Article

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trial

2025-03-10

Abstract excerpt

<title>Abstract</title> <p>Anchored immunotherapy is a novel approach for retaining high doses of drugs within the tumor microenvironment improving the therapeutic window . Tolododekin alfa is a first-in-class anchored drug conjugate in which IL-12 is linked to aluminum hydroxide. Safety and biologic activity was evaluated in a Phase 1 clinical trial in patients with accessible advanced solid tumors. The primary...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 45a4f36e-a1e6-5307-920b-34061f3aa442
DOI: 10.21203/rs.3.rs-5984691/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trialDOI 10.21203/rs.3.rs-5984691/v1Read

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trialSemantic proximity Read

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsSemantic proximity Read

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: A first-in-human phase 1 trialSemantic proximity Read

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid LeukemiaSemantic proximity Read

CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironmentSemantic proximity Read

Local Delivery of Accutox® Synergises With Immune-checkpoint Inhibitors at Disrupting Tumor GrowthSemantic proximity Read

Potent antitumor activity of a designed interleukin-21 mimicSemantic proximity Read

Drug-loaded Microbubble Delivery System to Enhance PD-L1 Blockade Immunotherapy with Remodeling Immune MicroenvironmentSemantic proximity Read

A First-in-human Phase I Study of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Patients With Advanced Solid Tumors With HER2 or HER3 Aberrations.Semantic proximity Read

Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potentialSemantic proximity Read

Membrane-anchored and tumor-targeted Il-12(attIL12) PBMC therapy for osteosarcomaSemantic proximity Read